Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck

The prognosis of patients with advanced head and neck cancer remain dismal. For this tumor type, elevated levels of EGFR are associated with a shorter disease free survival and time to treatment failure, reflecting a more aggressive phenotype. Nimotuzumab is a humanized monoclonal antibody that reco... View More